Your browser doesn't support javascript.
loading
Assessing IRAK4 Functions in ABC DLBCL by IRAK4 Kinase Inhibition and Protein Degradation.
Zhang, Jing; Fu, Liqiang; Shen, Bin; Liu, Yingtao; Wang, Wenqian; Cai, Xin; Kong, Linglong; Yan, Yilin; Meng, Ryan; Zhang, Zhuming; Chen, Ying-Nan P; Liu, Qian; Wan, Zhao-Kui; Zhou, Tianyuan; Wang, Xiaotao; Gavine, Paul; Del Rosario, Amanda; Ahn, Kay; Philippar, Ulrike; Attar, Ricardo; Yang, Jennifer; Xu, Yanping; Edwards, James P; Dai, Xuedong.
Afiliação
  • Zhang J; Oncology Biology, Janssen (China) Research & Development Center, Shanghai 201210, China.
  • Fu L; Medicinal Chemistry, Janssen (China) Research & Development Center, Shanghai 201210, China.
  • Shen B; Oncology Biology, Janssen (China) Research & Development Center, Shanghai 201210, China.
  • Liu Y; Medicinal Chemistry, Janssen (China) Research & Development Center, Shanghai 201210, China.
  • Wang W; Oncology Biology, Janssen (China) Research & Development Center, Shanghai 201210, China.
  • Cai X; Biomarker, Janssen (China) Research & Development Center, Shanghai 201210, China.
  • Kong L; Medicinal Chemistry, Janssen (China) Research & Development Center, Shanghai 201210, China.
  • Yan Y; Biomarker, Janssen (China) Research & Development Center, Shanghai 201210, China.
  • Meng R; Nonclinical Safety, Janssen (China) Research & Development Center, Shanghai 201210, China.
  • Zhang Z; Janssen Research & Development, LLC, 1400 McKean Road, Spring House, PA 19477, USA.
  • Chen YP; Oncology Biology, Janssen (China) Research & Development Center, Shanghai 201210, China.
  • Liu Q; Medicinal Chemistry, Janssen (China) Research & Development Center, Shanghai 201210, China.
  • Wan ZK; Medicinal Chemistry, Janssen (China) Research & Development Center, Shanghai 201210, China.
  • Zhou T; Oncology Biology, Janssen (China) Research & Development Center, Shanghai 201210, China.
  • Wang X; Biomarker, Janssen (China) Research & Development Center, Shanghai 201210, China.
  • Gavine P; Oncology Biology, Janssen (China) Research & Development Center, Shanghai 201210, China.
  • Del Rosario A; Janssen Research & Development, LLC, 1400 McKean Road, Spring House, PA 19477, USA.
  • Ahn K; Janssen Research & Development, LLC, 1400 McKean Road, Spring House, PA 19477, USA.
  • Philippar U; Janssen Research & Development, Turnhoutseweg 30, 2340 Beerse, Belgium.
  • Attar R; Janssen Research & Development, LLC, 1400 McKean Road, Spring House, PA 19477, USA.
  • Yang J; Oncology Biology, Janssen (China) Research & Development Center, Shanghai 201210, China.
  • Xu Y; Medicinal Chemistry, Janssen (China) Research & Development Center, Shanghai 201210, China.
  • Edwards JP; Janssen Research & Development, LLC, 1400 McKean Road, Spring House, PA 19477, USA.
  • Dai X; Medicinal Chemistry, Janssen (China) Research & Development Center, Shanghai 201210, China. Electronic address: xdai18@its.jnj.com.
Cell Chem Biol ; 27(12): 1500-1509.e13, 2020 12 17.
Article em En | MEDLINE | ID: mdl-32888499
The interleukin-1 receptor-activated kinase 4 (IRAK4) belongs to the IRAK family of serine/threonine kinases and plays a central role in the innate immune response. However, the function of IRAK4 in tumor growth and progression remains elusive. Here we sought to determine the enzymatic and scaffolding functions of IRAK4 in activated B-cell-like diffuse large B cell lymphoma (ABC DLBCL). We chose a highly selective IRAK4 kinase inhibitor to probe the biological effects of kinase inhibition and developed a series of IRAK4 degraders to evaluate the effects of protein degradation in ABC DLBCL cells. Interestingly, the results demonstrated that neither IRAK4 kinase inhibition nor protein degradation led to cell death or growth inhibition, suggesting a redundant role for IRAK4 in ABC DLBCL cell survival. IRAK4 degraders characterized in this study provide useful tools for understanding IRAK4 protein scaffolding function, which was previously unachievable using pharmacological perturbation.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfoma Difuso de Grandes Células B / Inibidores de Proteínas Quinases / Quinases Associadas a Receptores de Interleucina-1 / Proteólise Limite: Humans Idioma: En Revista: Cell Chem Biol Ano de publicação: 2020 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfoma Difuso de Grandes Células B / Inibidores de Proteínas Quinases / Quinases Associadas a Receptores de Interleucina-1 / Proteólise Limite: Humans Idioma: En Revista: Cell Chem Biol Ano de publicação: 2020 Tipo de documento: Article País de afiliação: China